By Fineline Cube Shanghai-based Hrain Biotechnology Co., Ltd. has announced receiving tacit clinical trial approval from the Center for Drug Evaluation (CDE) for its anti-CD70 T cell therapy, HR010. The therapy is intended for the treatment of advanced or metastatic renal cancer.
CD70 as a Potential Target for Kidney Cancer Treatment
CD70, a member of the tumor necrosis factor superfamily, is highly expressed in various malignant tumors, particularly kidney cancer, making it a potential target for treatment. HR010, an in-house developed CAR-T cell therapy, has demonstrated significant therapeutic effects in animal models, achieving complete tumor clearance.
HR010’s Therapeutic Effects and Immunological Memory
When the same tumor cells were inoculated into mice that had previously experienced tumor clearance through HR010 treatment, the proliferation of tumor cells continued to be inhibited, suggesting that HR010 can form immunological memory in mice. This capability to form immunological memory is a significant advancement in the field of cancer immunotherapy, as it may provide long-term protection against tumor recurrence.-Fineline Info & Tech